ArticleCell biochemistry and function2025
Protection of Adipose Tissue by Pioglitazone in a Mouse Model of Doxorubicin Treatment.
Article in Cell biochemistry and function, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From bench to bedside: adipose tissue fibrosis in obesity, anti-diabetic therapies, and bariatric surgery.The Korean journal of internal medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cancer is a global epidemic with increasing incidence, which needs continuous efforts to enhance treatment efficacy and reduce side effects. Our study focuses on the impact of doxorubicin, a widely used chemotherapeutic agent, on white adipose tissue (WAT) homeostasis and explores the potential mitigating effects of coadministration with pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPARγ) activator. Using male C57BL/6 mice, we investigated the influence of doxorubicin and pioglitazone on WAT, considering factors such as weight loss, metabolic parameters, lipolysis, adipokines, and immune cell infiltration. Doxorubicin treatment resulted in weight loss, specifically affecting visceral adipose tissue, while coadministration with pioglitazone preserved inguinal adipose tissue (iWAT). Metabolic analyses revealed that doxorubicin induced hypoglycaemia, mitigated by pioglitazone, without significant effects on lipid profiles. Pioglitazone ameliorated the doxorubicin-induced reduction in adiponectin, thereby contributing to the maintenance of glucose homeostasis. Lipolysis assays demonstrated doxorubicin-induced lipotoxicity, particularly in (iWAT), which was attenuated by pioglitazone. Histological analysis showed no significant changes in adipocyte size, while flow cytometry revealed a reduction in pro-inflammatory M1 macrophages in the co-treated group. Based on gene expression profiles, pioglitazone appeared to modulate genes involved in lipid metabolism, with preliminary indications of a potential role in adipogenic processes. In summary, coadministration of pioglitazone during doxorubicin treatment appeared to attenuate alterations in WAT homeostasis associated with lipotoxicity. These findings contribute to the understanding of potential supportive strategies during doxorubicin-based chemotherapy. Further studies should be conducted to define appropriate dosing regimens, treatment durations, and to evaluate potential effects on cancer progression and patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.